JAK Inhibitor News and Research

RSS
Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM announces updates on nimotuzumab clinical development program

YM announces updates on nimotuzumab clinical development program

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Top-line results from Pfizer's tofacitinib Phase 3 study in rheumatoid arthritis

Sequencing mouse cancer genome reveals mutations driving cancer in humans

Sequencing mouse cancer genome reveals mutations driving cancer in humans

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

JAK3 pathway highlighted as leukemia target

JAK3 pathway highlighted as leukemia target

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Ambit files registration statement with SEC for public offering of common stock

Ambit files registration statement with SEC for public offering of common stock

BioCryst receives $1.1 million in grants under QTDP program

BioCryst receives $1.1 million in grants under QTDP program

Pfizer announces tasocitinib Phase 2 data for plaque psoriasis

Pfizer announces tasocitinib Phase 2 data for plaque psoriasis

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

YM concludes dose-escalation in CYT387 Phase I/II clinical trial for myelofibrosis

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients